Hope Isn't a Strategy. Every Strategy Starts as One.

A plan can be approved, sized, scheduled and fully staffed and still be hope wearing a plan's costume. The difference is three things you can write down, and most companies never write the third one.

There is a particular kind of relief in the room when a big move gets announced. The reorganisation. The spin-off. The rebrand. The new platform. Everyone has been carrying the problem for so long that the announcement itself feels like progress, and for a few weeks it genuinely is. Nobody asks the awkward question, because the move is large, and it is happening, and surely something that large will do something.

Hope is not a strategy is one of the oldest lines in management. It is also, as normally used, close to useless, because it gets aimed at the wrong target. It is used to scold optimism. Optimism was never the problem. The problem is that hope does not usually show up looking hopeful. It shows up looking like a plan: board-approved, costed out, with a timeline and a project team and a name.

The test is not whether a move is specified. It is whether it reaches the cause.

A split, then a reversal

In September 2025, Kraft Heinz announced it would separate into two independent public companies. One would hold the sauces and spreads, the part that was still working. The other would hold the grocery staples. The stated reasoning was the reasoning these announcements always carry: two more focused organisations, less complexity, brands better able to compete. The board approved it. A new chief executive was hired specifically to run it through, arriving on the first of January.

Six weeks later, on February 11, 2026, he stopped it.

What makes this worth studying is not the reversal. Companies reverse things all the time, usually while insisting they haven't. What makes it worth studying is that he said out loud what the split had never addressed.

"We have historically underinvested in our brands."

Steve Cahillane, CEO, Kraft Heinz · Q4 earnings call, February 11, 2026

He went on to tie that underinvestment directly to persistent share loss across the previous decade. Notably, he did not say the split had been a mistake. He said the board had reached a reasonable conclusion with what it had. That is the honest version, and it is the one worth sitting with, because the split was not stupid. It was structural. And the problem was not structural.

Reorganising which company owns which brand does not change whether anyone wants the food.

What the numbers had been saying the whole time

The 2025 results carried the diagnosis in a single line, for anyone reading the composition rather than the headline. Organic sales fell 3.4 percent for the year. Inside that number, price was up 0.7 points and volume and mix were down 4.1 points.

Read plainly: the company was charging more and selling less. Fewer units, leaving the shelf, at higher prices. That is not a complexity problem and no amount of corporate architecture touches it. It is the signature of a business capturing value faster than it creates any, and it can hold up the revenue line for years while the thing underneath quietly empties out. The near ten billion dollars of brand write-downs booked that year were the accounting system catching up to what the volume line had been saying for a decade.

Three things that turn hope into a path

The same day the split was paused, the company announced it would put six hundred million dollars into marketing, sales, research and development, product quality and price. On its own, that is just a different big move, and big moves are cheap to announce. What separates it is not the size. It is that it carried three specifications the split never did.

The second row is the rare one, and it is the one I would ask you to steal.

They published the bill before they published the benefit. Guidance issued that morning said full-year organic sales would fall, that operating income would drop by double digits precisely because of the investment, and that earnings would land below what analysts were expecting. A company announcing a turnaround told the market that its numbers would get worse first, and put a range on how much worse.

That is what a costed path looks like, and almost nobody does it, because publishing the cost is the part that can make you look wrong in public. It is much safer to announce the benefit and let the cost arrive quietly, one quarter at a time, where it can be attributed to the weather.

Six months in, the test is running

By the second quarter of 2026, reported on August 5, the decline had narrowed considerably. Organic sales were down 1.3 percent against down 4.2 percent two quarters earlier. The company raised its full-year sales outlook, raised its earnings outlook, and then raised the investment itself by another hundred million. Only about a third of the original money had been spent.

And it still might not work

This is the part where a piece like this normally lands the plane, and it shouldn't.

Organic sales are still negative. The second quarter carried a further seven point four billion dollars of non-cash impairment, on top of the nine point three billion the year before. Third-quarter guidance is worse than the second quarter, not better. And the company is still taking price while it invests, which is the same lever that helped hollow out the volume line in the first place.

So the honest reading is narrow and it is specific: the path is working on the leading indicator and has not yet worked on the lagging one. That is a real thing to know and it is not the same as a recovery. Anyone telling you in August 2026 that this turnaround has succeeded is doing exactly what the split did, which is offering a conclusion the evidence has not reached.

Your version is smaller and it is the same

Almost nobody reading this is allocating six hundred million dollars. It does not matter. The shape is identical at every scale, and it is probably sitting in your plan right now: the rebrand, the new sales hire, the platform migration, the second product line, the agency review, the market you are about to enter.

Ask the first question first. Does the move reach the cause, or does it rearrange the furniture around the cause? A rebrand does not fix a product people have stopped enjoying. A new salesperson does not fix an offer nobody wants at that price. Restructuring the team does not fix work the client no longer values. These are all real moves, fully specifiable, and none of them touch the thing that is actually happening.

Then apply the three tests, and expect to fail the second one. Naming the move is easy. Setting a test is uncomfortable but doable. Writing down what it will cost you, in advance, where someone else can see it, is the part almost everyone skips, and skipping it is precisely what lets a plan stay hopeful indefinitely. If the bill never got written down, the plan can never be seen to be expensive, and if it can never be seen to be expensive, it never has to be judged.

Hope is not the enemy here. Hope is the raw material. Every strategy worth running started as somebody hoping something would work. It stops being hope, and starts being a path, at the exact moment you name the move, price it out loud, and say what you will accept as evidence it isn't working.